Literature DB >> 15523090

Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.

Koji Matsumoto1, Graham R Leggatt, Jie Zhong, Xiaosong Liu, Rachel L de Kluyver, Tania Peters, Germain J P Fernando, Amy Liem, Paul F Lambert, Ian H Frazer.   

Abstract

BACKGROUND: Although immunization with tumor antigens can eliminate many transplantable tumors in animal models, immune effector mechanisms associated with successful immunotherapy of epithelial cancers remain undefined.
METHODS: Skin from transgenic mice expressing the cervical cancer-associated tumor antigen human papillomavirus type 16 (HPV16) E6 or E7 proteins from a keratin 14 promoter was grafted onto syngeneic, non-transgenic mice. Skin graft rejection was measured after active immunization with HPV16 E7 and adoptive transfer of antigen-specific T cells. Cytokine secretion of lymphocytes from mice receiving skin grafts and immunotherapy was detected by enzyme-linked immunosorbent assay, and HPV16 E7-specific memory CD8+ T cells were detected by flow cytometry and ELISPOT.
RESULTS: Skin grafts containing HPV16 E6-or E7-expressing keratinocytes were not rejected spontaneously or following immunization with E7 protein and adjuvant. Adoptive transfer of E7-specific T-cell receptor transgenic CD8+ T cells combined with immunization resulted in induction of antigen-specific interferon gamma-secreting CD8+ T cells and rejection of HPV16 E7-expressing grafts. Specific memory CD8+ T cells were generated by immunotherapy. However, a further HPV16 E7 graft was rejected from animals with memory T cells only after a second E7 immunization.
CONCLUSIONS: Antigen-specific CD8+ T cells can destroy epithelium expressing HPV16 E7 tumor antigen, but presentation of E7 antigen from skin is insufficient to reactivate memory CD8+ T cells induced by immunotherapy. Thus, effective cancer immunotherapy in humans may need to invoke sufficient effector as well as memory T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15523090     DOI: 10.1093/jnci/djh301

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

1.  HPV researchers set sights on preventing skin cancers.

Authors:  Simon Grose
Journal:  Nat Med       Date:  2009-01       Impact factor: 53.440

2.  IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.

Authors:  Christina Gosmann; Stephen R Mattarollo; Jennifer A Bridge; Ian H Frazer; Antje Blumenthal
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

Review 3.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

4.  IL-1 signalling determines the fate of skin grafts expressing non-self protein in keratinocytes.

Authors:  Usriansyah Hadis; Graham R Leggatt; Ranjeny Thomas; Ian H Frazer; Eva M Kovacs
Journal:  Exp Dermatol       Date:  2010-08       Impact factor: 3.960

5.  NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins.

Authors:  Stephen R Mattarollo; Michelle Yong; Christina Gosmann; Allison Choyce; Dora Chan; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

6.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

7.  A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

Authors:  Cornelia L Trimble; Shiwen Peng; Ferdynand Kos; Patti Gravitt; Raphael Viscidi; Elizabeth Sugar; Drew Pardoll; T C Wu
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

Review 8.  Development of therapeutic HPV vaccines.

Authors:  Cornelia L Trimble; Ian H Frazer
Journal:  Lancet Oncol       Date:  2009-10       Impact factor: 41.316

9.  Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses.

Authors:  Wenyi Gu; Melanie Cochrane; Graham R Leggatt; Elizabeth Payne; Allison Choyce; Fang Zhou; Robert Tindle; Nigel A J McMillan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-04       Impact factor: 11.205

10.  Cytotoxic and immunomodulatory effects of polyhydroxyoctane isolated from Lentinus polychrous mycelia.

Authors:  Niramai Fangkrathok; Jintana Junlatat; Kaoru Umehara; Hiroshi Noguchi; Bungorn Sripanidkulchai
Journal:  J Nat Med       Date:  2013-08-15       Impact factor: 2.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.